Healthcare

WHO urges stronger ethics oversight for AI health research

The WHO called for stronger oversight of AI-enabled health research while pharmaceutical companies expand AI use in drug discovery, molecular design and clinical-trial planning.

A World Economic Forum health briefing reported that the World Health Organization is calling for stronger ethical oversight of AI in health research. The WHO warned that innovation should not outpace safeguards for human rights, equity, privacy and public trust.

The recommendations apply across the research lifecycle and involve researchers, ethics committees, regulators, funders and publishers. The WHO said these groups need stronger scrutiny of AI-enabled research and greater expertise to assess risks.

Specific concerns include transparency, bias, accountability and potential harms, particularly as AI tools spread unevenly across healthcare systems. The report also notes that pharmaceutical companies are increasing investment in AI for drug discovery, molecule design and clinical-trial planning.

The development matters because it pairs rapid practical adoption with calls for governance. As AI moves from research laboratories into drug development and clinical settings, the WHO’s position indicates that oversight capacity, data protection and public confidence will be central to sustainable healthcare deployment.

Original source: World Economic Forum

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI